Affiliation:
1. Department of Gynecologic Oncology, The First Hospital of Jilin University, Changchun, Jilin, China
2. Weiming Environmental Molecular Diagnostics (Changshu) Co.Ltd. Changshun, Jiangsu, China
3. College of New Energy and Environment, Key Lab of Groundwater Resource and Environment Ministry of Education, Jilin University, Changchun, Jilin, China
Abstract
BACKGROUND: Epithelial ovarian cancer (EOC) is the leading cause of death from gynecologic malignancies. The poor prognosis of EOC is mainly due to its asymptomatic early stage, lack of effective screening methods, and a late diagnosis in the advanced stages of the disease. OBJECTIVE: This study investigated metabolomic abnormalities in epithelial ovarian cancers. METHODS: Our study developed a novel strategy to rapidly identify the metabolic biomarkers in the plasma of the EOC patients using Internal Extraction Electrospray Ionization Mass Spectrometry (IEESI-MS) and Liquid Chromatography-mass Spectrometry (HPLC-MS), which could distinguish the differential metabolites in between plasma samples collected from 98 patients with epithelial ovarian cancer, including 78 cases with original (P), and 20 cases with self-configuration (ZP), as well as 60 healthy subjects, including 30 cases in the original sample (H), 30 cases in self-configuration (ZH), and 6 cases in a blind sample (B). RESULTS: Our study detected 880 metabolites based on criteria variable importance in projection (VIP) > 1, among which 26 metabolites were selected for further identification. They are mainly metabolism-related lipids, amino acids, nucleic acids, and others. The metabolic pathways associated with the differential metabolites were explored by the KEGG analysis, a comprehensive database that integrates genome, chemistry, and system function information. The abnormal metabolites of EOC patients identified by IEESI-MS and HPLC-MS included Lysophosphatidylcholine (16:0) [Lyso PC (16:0)], L-Phenylalanine, L-Leucine, Phenylpyruvic acid, L-Tryptophan, and L-Histidine. CONCLUSIONS: Identifying the abnormal metabolites of EOC patients through metabolomics analyses could provide a new strategy to identify valuable potential biomarkers for the screening and early diagnosis of EOC.
Subject
Cancer Research,Genetics,Oncology,General Medicine
Reference65 articles.
1. Ovarian cancer;Jayson;Lancet (London, England),2014
2. Ovarian cancer statistics, 2018;Torre;CA: A Cancer Journal for Clinicians,2018
3. Ovarian carcinomas: Five distinct diseases with different origins, genetic alterations, and clinicopathological features;Prat;Virchows Archiv: An International Journal of Pathology,2012
4. Pre-diagnosis and post-diagnosis use of common analgesics and ovarian cancer prognosis (NHS/NHSII): A cohort study;Merritt;The Lancet. Oncology,2018
5. Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology;Armstrong;Journal of the National Comprehensive Cancer Network: JNCCN,2021
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献